The Wrap Is Right Reflux for 100
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Pathophysiology, Differential Diagnosis and Management of Rumination Syndrome Kathleen Blondeau, Veerle Boecxstaens, Nathalie Rommel, Jan Tack
Review article: pathophysiology, differential diagnosis and management of rumination syndrome Kathleen Blondeau, Veerle Boecxstaens, Nathalie Rommel, Jan Tack To cite this version: Kathleen Blondeau, Veerle Boecxstaens, Nathalie Rommel, Jan Tack. Review article: pathophysiol- ogy, differential diagnosis and management of rumination syndrome. Alimentary Pharmacology and Therapeutics, Wiley, 2011, 33 (7), pp.782. 10.1111/j.1365-2036.2011.04584.x. hal-00613928 HAL Id: hal-00613928 https://hal.archives-ouvertes.fr/hal-00613928 Submitted on 8 Aug 2011 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. Alimentary Pharmacology & Therapeutic Review article: pathophysiology, differential diagnosis and management of rumination syndrome ForJournal: Alimentary Peer Pharmacology Review & Therapeutics Manuscript ID: APT-1105-2010.R2 Wiley - Manuscript type: Review Article Date Submitted by the 09-Jan-2011 Author: Complete List of Authors: Blondeau, Kathleen; KULeuven, Lab G-I Physiopathology Boecxstaens, Veerle; University of Leuven, Center for Gastroenterological Research Rommel, Nathalie; University of Leuven, Center for Gastroenterological Research Tack, Jan; University Hospital, Center for Gastroenterological Research Functional GI diseases < Disease-based, Oesophagus < Organ- Keywords: based, Diagnostic tests < Topics, Motility < Topics Page 1 of 24 Alimentary Pharmacology & Therapeutic 1 2 3 EDITOR'S COMMENTS TO AUTHOR: 4 Please consider the points raised by the reviewers. -
A Drug Repositioning Approach Identifies Tricyclic Antidepressants As Inhibitors of Small Cell Lung Cancer and Other Neuroendocrine Tumors
Published OnlineFirst September 26, 2013; DOI: 10.1158/2159-8290.CD-13-0183 RESEARCH ARTICLE A Drug Repositioning Approach Identifi es Tricyclic Antidepressants as Inhibitors of Small Cell Lung Cancer and Other Neuroendocrine Tumors Nadine S. Jahchan 1 , 2 , Joel T. Dudley 1 , Pawel K. Mazur 1 , 2 , Natasha Flores 1 , 2 , Dian Yang 1 , 2 , Alec Palmerton 1 , 2 , Anne-Flore Zmoos 1 , 2 , Dedeepya Vaka 1 , 2 , Kim Q.T. Tran 1 , 2 , Margaret Zhou 1 , 2 , Karolina Krasinska 3 , Jonathan W. Riess 4 , Joel W. Neal 5 , Purvesh Khatri 1 , 2 , Kwon S. Park 1 , 2 , Atul J. Butte 1 , 2 , and Julien Sage 1 , 2 Downloaded from cancerdiscovery.aacrjournals.org on September 29, 2021. © 2013 American Association for Cancer Research. Published OnlineFirst September 26, 2013; DOI: 10.1158/2159-8290.CD-13-0183 ABSTRACT Small cell lung cancer (SCLC) is an aggressive neuroendocrine subtype of lung cancer with high mortality. We used a systematic drug repositioning bioinformat- ics approach querying a large compendium of gene expression profi les to identify candidate U.S. Food and Drug Administration (FDA)–approved drugs to treat SCLC. We found that tricyclic antidepressants and related molecules potently induce apoptosis in both chemonaïve and chemoresistant SCLC cells in culture, in mouse and human SCLC tumors transplanted into immunocompromised mice, and in endog- enous tumors from a mouse model for human SCLC. The candidate drugs activate stress pathways and induce cell death in SCLC cells, at least in part by disrupting autocrine survival signals involving neurotransmitters and their G protein–coupled receptors. The candidate drugs inhibit the growth of other neuroendocrine tumors, including pancreatic neuroendocrine tumors and Merkel cell carcinoma. -
DBL™ Promethazine Hydrochloride Injection BP
DBL™ Promethazine Hydrochloride Injection BP 1. NAME OF THE MEDICINE Promethazine hydrochloride 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each mL of the solution contains 25.0 mg promethazine hydrochloride, 0.10 mg disodium edetate, 1.30 microlitre glacial acetic acid, 27.2 mg sodium acetate and 1.32 mg sodium metabisulfite in water for injections. Excipient(s) with known effect Sodium metabisulfite For the full list of excipients, see section 6.1 List of Excipients. 3. PHARMACEUTICAL FORM Solution for injection. DBL™ Promethazine Hydrochloride Injection BP is a clear, colourless solution of pH 5.0 to 6.0. 4. CLINICAL PARTICULARS 4.1 Therapeutic Indications DBL™ Promethazine Hydrochloride Injection BP is indicated for the following conditions: Treatment of allergic reactions such as: uncomplicated allergic conditions of the immediate type, e.g., pruritus, urticaria and angioedema, when oral therapy is impossible or contraindicated. Treatment and prevention of vomiting including: motion sickness; drug induced nausea; prevention and control of nausea and vomiting associated with certain types of anaesthesia and surgery, such as procedures with a high incidence of post-operative vomiting (e.g., gynaecological surgery, strabismus or middle ear surgery, and electroconvulsive therapy); in patients with a past history of motion sickness or post- operative vomiting; and in patients in whom avoidance of vomiting is crucial (e.g., neurosurgery and eye surgery). Page 1 of 10 Promethazine has sedative effects and it is also used in: pre-operative, post-operative and obstetric (during labour) sedation. 4.2 Dose and Method of Administration Dosage Allergic conditions Adults: 25 mg to 50 mg by deep intramuscular injection or slow intravenous injection; may be repeated within two hours if necessary. -
Operative Nausea and Vomiting in Lower-Segment Caesarean Section
International Journal of Research in Medical Sciences Rashmi et al. Int J Res Med Sci. 2016 Jun;4(6):2177-2180 www.msjonline.org pISSN 2320-6071 | eISSN 2320-6012 DOI: http://dx.doi.org/10.18203/2320-6012.ijrms20161781 Research Article Effectiveness of metoclopramide in preventing the incidence of post- operative nausea and vomiting in lower-segment caesarean section 1 1 2 Rashmi *, Shivanand PT , Manjunath ML 1Department of Anaesthesiology, Shivamogga Institute of Medical Sciences, Shivamogga, Karnataka, India 2Department of Physiology, Shivamogga Institute of Medical Sciences, Shivamogga, Karnataka, India Received: 04 April 2016 Accepted: 09 May 2016 *Correspondence: Dr. Rashmi, E-mail: [email protected] Copyright: © the author(s), publisher and licensee Medip Academy. This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. ABSTRACT Background: The common and distressing symptoms which follow anaesthesia and surgery are pain, nausea and vomiting. Nausea and vomiting are the most common side effects in the post- anaesthesia care unit. But post- operative nausea and vomiting have received less attention, though there are extensive literature, data are frequently difficult to interpret and compare. Therefore, the present study was undertaken to investigate the efficacy and safety of IV Metoclopramide as prophylaxis for postoperative nausea and vomiting in lower-segment caesarean section (LSCS) under spinal anaesthesia. Methods: After institutional approval and informed consent fifty ASA I and II patients undergoing non-emergent LSCS taken for study. The patients received IV Metoclopramide 10 mg. -
United States Patent (19) 11 Patent Number: 6,060,642 Tecott Et Al
US006060642A United States Patent (19) 11 Patent Number: 6,060,642 Tecott et al. (45) Date of Patent: May 9, 2000 54 SEROTONIN 5-HT6 RECEPTOR KNOCKOUT Roth, Bryan L., et al., “Binding of Typical and Atypical MOUSE Antipsychotic Agents 5-Hydroxytryptamine-6 and 5-Hydroxytryptamine–7 Receptors'." The Journal Of Phar 75 Inventors: Laurence H. Tecott, San Francisco; macology and Experimental Therapeutics (1994) vol. 268, Thomas J. Brennan, San Carlos, both No. (3):1403–1410. of Calif. Ruat, Martial, et al., “A Novel Rat Serotonin (5-HT) 73 Assignee: The Regents of the University of Receptor: Molecular Cloning, Localization And Stimulation Of cAMP Accumulation,” Biochemical and Biophysical California, Oakland, Calif. Communications Research Communications (May 28, 1993) 21 Appl. No.: 09/132,388 vol. 193, No. (1):268–276. Saudou, Frédéric, et al., “5-Hydroxytryptamine Receptor 22 Filed: Aug. 11, 1998 Subtypes. In Vertebrates And Inverterbrates,” Neurochem Int. (1994) vol. 25, No. (6):503–532. Related U.S. Application Data Sleight, A.J., et al., “Effects of Altered 5-HT Expression. In 60 Provisional application No. 60/055.817, Aug. 15, 1997. The Rat: Functional Studies Using Antisense Oligonucle 51 Int. Cl." ............................. C12N 5700; C12N 15/12; otides,” Behavioural Brain Research (1996) vol. AO1K 67/027; G01N 33/15; CO7H 21/04 73:245-248. 52 U.S. Cl. ................................... 800/3; 800/18; 800/21; Tecott, Laurence H., et al., “Behavioral Genetics: Genes And 800/9; 435/172.1; 435/1723; 435/325; Aggressiveness,” Current Biology (1996) vol. 6, No. 435/455; 536/23.5 (3):238–240. 58 Field of Search ................................... -
ZOFRAN® (Ondansetron Hydrochloride) Injection
PRESCRIBING INFORMATION ZOFRAN® (ondansetron hydrochloride) Injection DESCRIPTION The active ingredient in ZOFRAN Injection is ondansetron hydrochloride (HCl), the racemic form of ondansetron and a selective blocking agent of the serotonin 5-HT3 receptor type. Chemically it is (±) 1, 2, 3, 9-tetrahydro-9-methyl-3-[(2-methyl-1H-imidazol-1-yl)methyl]-4H carbazol-4-one, monohydrochloride, dihydrate. It has the following structural formula: The empirical formula is C18H19N3O•HCl•2H2O, representing a molecular weight of 365.9. Ondansetron HCl is a white to off-white powder that is soluble in water and normal saline. Sterile Injection for Intravenous (I.V.) or Intramuscular (I.M.) Administration: Each 1 mL of aqueous solution in the 2-mL single-dose vial contains 2 mg of ondansetron as the hydrochloride dihydrate; 9.0 mg of sodium chloride, USP; and 0.5 mg of citric acid monohydrate, USP and 0.25 mg of sodium citrate dihydrate, USP as buffers in Water for Injection, USP. Each 1 mL of aqueous solution in the 20-mL multidose vial contains 2 mg of ondansetron as the hydrochloride dihydrate; 8.3 mg of sodium chloride, USP; 0.5 mg of citric acid monohydrate, USP and 0.25 mg of sodium citrate dihydrate, USP as buffers; and 1.2 mg of methylparaben, NF and 0.15 mg of propylparaben, NF as preservatives in Water for Injection, USP. ZOFRAN Injection is a clear, colorless, nonpyrogenic, sterile solution. The pH of the injection solution is 3.3 to 4.0. CLINICAL PHARMACOLOGY Pharmacodynamics: Ondansetron is a selective 5-HT3 receptor antagonist. -
Medications to Be Avoided Or Used with Caution in Parkinson's Disease
Medications To Be Avoided Or Used With Caution in Parkinson’s Disease This medication list is not intended to be complete and additional brand names may be found for each medication. Every patient is different and you may need to take one of these medications despite caution against it. Please discuss your particular situation with your physician and do not stop any medication that you are currently taking without first seeking advice from your physician. Most medications should be tapered off and not stopped suddenly. Although you may not be taking these medications at home, one of these medications may be introduced while hospitalized. If a hospitalization is planned, please have your neurologist contact your treating physician in the hospital to advise which medications should be avoided. Medications to be avoided or used with caution in combination with Selegiline HCL (Eldepryl®, Deprenyl®, Zelapar®), Rasagiline (Azilect®) and Safinamide (Xadago®) Medication Type Medication Name Brand Name Narcotics/Analgesics Meperidine Demerol® Tramadol Ultram® Methadone Dolophine® Propoxyphene Darvon® Antidepressants St. John’s Wort Several Brands Muscle Relaxants Cyclobenzaprine Flexeril® Cough Suppressants Dextromethorphan Robitussin® products, other brands — found as an ingredient in various cough and cold medications Decongestants/Stimulants Pseudoephedrine Sudafed® products, other Phenylephrine brands — found as an ingredient Ephedrine in various cold and allergy medications Other medications Linezolid (antibiotic) Zyvox® that inhibit Monoamine oxidase Phenelzine Nardil® Tranylcypromine Parnate® Isocarboxazid Marplan® Note: Additional medications are cautioned against in people taking Monoamine oxidase inhibitors (MAOI), including other opioids (beyond what is mentioned in the chart above), most classes of antidepressants and other stimulants (beyond what is mentioned in the chart above). -
(Tricyclic Antidepressants (TCA) and Selective Serotonin Reuptake
Antidepressants (Tricyclic Antidepressants and Selective Serotonin Reuptake Inhibitors) in treatment of adults with depression Q 1: Are antidepressants (Tricyclic Antidepressants (TCA) and Selective Serotonin Reuptake Inhibitors (SSRI)) better (more effective than/as safe as) than treatment as usual (placebo) in adults with depressive episode/disorder? Background The relative merits of antidepressants versus placebo for depression have been given considerable scientific attention in recent years. This document covers the use of TCAs and SSRIs as acute phase treatment for depressive episode/disorder. Population/Intervention(s)/Comparison/Outcome(s) (PICO) Population: adults with depressive episode/disorder Interventions: antidepressant medicines: TCAs, SSRIs Comparison: placebo Outcomes: o treatment effectiveness in terms of reduction of symptoms o treatment effectiveness in terms of improvement in functioning o acceptability profile o suicide related outcomes List of the systematic reviews identified by the search process INCLUDED IN GRADE TABLES OR FOOTNOTES 1 Antidepressants (Tricyclic Antidepressants and Selective Serotonin Reuptake Inhibitors) in treatment of adults with depression Arroll B et al (2005). Efficacy and tolerability of tricyclic antidepressants and SSRIs compared with placebo for treatment of depression in primary care: a meta- analysis. Annals of Family Medicine, 3:449-56. Barbui C et al. (2007).Treatment discontinuation with selective serotonin reuptake inhibitors (SSRIs) versus tricyclic antidepressants (TCAs). Cochrane Database of Systematic Reviews, (3):CD002791. Furukawa TA, McGuire H, Barbui C (2002). Meta-analysis of effects and side effects of low dosage tricyclic antidepressants in depression: systematic review. British Medical Journal, 325:991. Geddes JR et al (2007). Selective serotonin reuptake inhibitors (SSRIs) versus other antidepressants for depression. Cochrane Database of Systematic Reviews, (3):CD001851. -
The 5-HT3 Receptor Antagonists
Ambulatory Surgery 7 (1999) 111–122 Current therapy for management of postoperative nausea and vomiting: the 5-HT3 receptor antagonists Pierre Diemunsch a,*, Kari Korttila b, Anthony Kovac c a Experimental Anesthesiology Unit, Hoˆpitaux Uni6ersitaires, 1 Place de 1-hopital, 67091 Strasbourg Cedex, France b Department of Obstetrics and Gynaecology, Uni6ersity of Helsinki, Haartmaninkatu-2, Fin-00290 Helsinki, Finland c Department of Anesthesiology, Uni6ersity of Kansas Medical Center, Kansas City KS, USA Received 27 June 1998; received in revised form 6 July 1998; accepted 2 September 1998 Abstract The control of postoperative nausea and vomiting (PONV) remains a problem in spite of the improvements achieved with newer anesthetic agents, such as propofol, and newer antiemetics. Management of PONV is difficult, this is most likely due to the multiple receptors and neurotransmitters in the central nervous system that mediate the emetic response, and to the multifactorial etiology of PONV. Studies of the four major 5-hydroxytryptamine (serotonin) subtype-3 (5-HT3) receptor antagonists suggest that they have similar safety and efficacy for prevention and treatment of PONV. These drugs lack the significant side effects observed with traditional antiemetics. Combination regimens of 5-HT3 receptor antagonists and traditional antiemetics can improve antiemetic efficacy. Areas of future study include comparing the cost effectiveness of these agents and determining optimal combinations of antiemetics to further reduce the incidence of PONV. © 1998 Elsevier Science B.V. All rights reserved. Keywords: Antiemetic; Postoperative nausea and vomiting; PONV; 5-HT3 receptor antagonist 1. Introduction When these occur after outpatient surgery, emergency admissions to the hospital can result [4]. -
Myasthenia Gravis Or Lambert-Eaton Myasthenia Syndrome – Medicines That May Affect Patients
CLINICAL GUIDELINE Myasthenia Gravis or Lambert-Eaton Myasthenia Syndrome – Medicines that may affect patients A guideline is intended to assist healthcare professionals in the choice of disease-specific treatments. Clinical judgement should be exercised on the applicability of any guideline, influenced by individual patient characteristics. Clinicians should be mindful of the potential for harmful polypharmacy and increased susceptibility to adverse drug reactions in patients with multiple morbidities or frailty. If, after discussion with the patient or carer, there are good reasons for not following a guideline, it is good practice to record these and communicate them to others involved in the care of the patient. Version Number: 1 Does this version include n/a changes to clinical advice: Date Approved: 11th July 2018 Date of Next Review: 30th July 2021 Lead Author: Lesley Murray Approval Group: Medicines Utilisation Subcommittee of ADTC Important Note: The Intranet version of this document is the only version that is maintained. Any printed copies should therefore be viewed as ‘Uncontrolled’ and as such, may not necessarily contain the latest updates and amendments. Information for healthcare professionals Medicines that may affect patients with Myasthenia Gravis or Lambert-Eaton Myasthenic Syndrome There are certain medicines that have been reported to worsen or induce myasthenia gravis (MG), often by increasing muscular weakness, and should be used with caution in patients with this condition. The list of medicines in table 1 has been compiled to assist prescribers in the decision making process when prescribing medicines for patients with myasthenia gravis. The medicines in this list have been classed according to those which should be: ▲ ▲Absolutely contraindicated ▲ Avoided Used with caution Probably safe with patient monitoring. -
Depression After Cyproheptadine: MAO Treatment
Correspondence BIOL PSYCHIATRY 1i 77 1992;31:1172-1183 Rohrbaugh JW, Gaillard AWK (1983): Sensory and motor acetic acid levels in the cerebrospinal fluid of depressive aspects of contingent negativevariation. In Gaillard AWK, patients treated with pmbenecid. Nature 225:1259-1260. Ritter W (eds), Tutorials in ERP Research: Endogenous Van Praag HM, Kalm RS, Asnis GM, et al (1987): Den- Components. Amsterdam: Elsevier, pp 269-31 I. olosization of biological psychiatry or the specificity of Swerdlow NR, Koob GF (1987): Dopamine, schizophrenia, 5-HT disturbances in psychiatric discrders. J Affective mania and depression: Toward a unified hypothesis of Disord 13:1-8. cortico-striato-pallidothalamic function. Behav Brain Sci Walter WG, Cooper R, Aldridge VJ, McCallum WC, Win- 10:197-245. ter A (1964): Contingent negative variation: An electric Tyrer P, Owen RT, Cicchetti DV (1984): The brief scale sign of ~nsori-mot.or association of expectancy in the for anxiety: A subdivision of the comprehensive psy- humaii brain Nature 203:380-384. chopathological rating scale. J Neurol Neurosurg Psy- Widl6cher D (! 983): Psychomotorretardation: Clinical, the- chiatry 47:970-975. oretical and psychometric aspects. Psychiat Clin North Van Praag HM, Korf J, Puite J (1970): 5-Hydmxyindole- Am 6:27-40. Depression after Cyproheptadine: initial evaluation. Although no actual suicide attempts were reported, he described almost constant suicidal MAO Treatment ideation, which he resisted by increasing his physical To the Editor: activity until exhaustion. Cyproheptadine has been reported to be effec- During the year prior to evaluation, he had been tive in the treatment of anorgasmia induced by the attending weekly outpatient psychotherapy. -
(12) Patent Application Publication (10) Pub. No.: US 2004/0110734 A1 Sackeyflo Et Al
US 2004O110734A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2004/0110734 A1 Sackeyflo et al. (43) Pub. Date: Jun. 10, 2004 (54) COMBINATIONS FOR THE TREATMENT OF (22) Filed: Nov. 19, 2003 NFLAMMATORY DISORDERS Related U.S. Application Data (76) Inventors: Robyn Sackeyflo, Ann Arbor, MI (US); Jason Fong, Philadelphia, PA (US); (63) Continuation of application No. 10/191,149, filed on Nicole Hurst, Boston, MA (US); Jul. 9, 2002. Palaniyandi Manivasakam, Brighton, MA (US); Edward Roydon Jost-Price, (60) Provisional application No. 60/304,089, filed on Jul. West Roxbury, MA (US); Grant 9, 2001. Zimmermann, Somerville, MA (US); Curtis Keith, Boston, MA (US); Alexis Publication Classification Borisy, Boston, MA (US) 51)1) Int. Cl.Cl." ..................... A61K 31/573573; A61K 31/553;55 Correspondence Address: A61K 31/554 CLARK & ELBING LLP (52) U.S. Cl. ..................... 514/171; 514/221; 514/211.13 101 FEDERAL STREET BOSTON, MA 02110 (US) (57) ABSTRACT The invention features methods and compositions for the (21) Appl. No.: 10/716,823 treatment of immunonflammatory disorders. US 2004/0110734 A1 Jun. 10, 2004 COMBINATIONS FOR THE TREATMENT OF SUMMARY OF THE INVENTION NFLAMMATORY DISORDERS 0008 We have discovered that the combination of amox CROSS-REFERENCE TO RELATED apine (2-cloro-11(1-piperazinyl)dibenzb,f1,4oxapine) APPLICATIONS and prednisolone (also known as 1-dehydrocortisol, 1-de 0001. This application is a continuation of U.S. Utility hydrohydrocortisone; 1,4-pregnadiene-11beta, 17alpha,21 application Ser. No. 10/191,149, filed Jul. 9, 2002, which triol-3,20-dione; and 11beta, 17alpha,21-trihydroxy-1,4- claims the benefit of U.S.